European regulators have recommended expanding use of the IL-23 inhibitor Skyrizi to treat moderate-to-severe plaque psoriasis in children aged 6 years or older who require systemic therapy.
Medscape News Europe
Source link : https://www.medscape.com/viewarticle/pediatric-plaque-psoriasis-treatment-set-expand-europe-2026a1000dbx?src=rss
Author :
Publish date : 2026-04-27 13:47:00
Copyright for syndicated content belongs to the linked Source.
